Archive
Ambusol AB (publ) – Emissionsutfall 2025 11 28 (PDF) Emissionen som löpte mellan 6 oktober – 17 november 2025 har stängts med en teckningslikvid uppgående till 7 MSEK, motsvarande en täckningsgrad om drygt 57 % av erbjudandet om 12,25 MSEK. Som tidigare offentliggjorts, beslutade styrelsen i Ambusol AB (publ) den 23 oktober, 2025 att förlänga […]
Ambusol beslutar om förlängd teckningsperiod i det pågående Erbjudandet. Styrelsen i Ambusol AB (publ) har den 23 oktober, 2025 beslutat att förlänga teckningsperioden i det pågående Erbjudandet att teckna aktier i Bolaget, riktat till Bolagets aktieägare, allmänheten och till en speciellt utvald krets av större investerare i Sverige och internationellt. Beslutet innebär att teckningsperioden förlängs […]
Share Issue 2025 The Company’s Board of Directors resolved on October 1st, 2025, with the support of the authorization from the shareholders’ meeting on June 26, 2025, to conduct a share issue without preferential rights for the company’s shareholders, in accordance with the key terms outlined here below: Issue size: 12,25M SEK, corresponding to70 000 new […]
Collaboration agreement The Company and Fluicell signed a collaboration agreement on September 2, 2025, to advance joint efforts in catheter development.
Ambusol secures exclusive global rights to fluicell’s microfluidic technology Ambusol AB (publ) has entered an exclusive global licensing and development agreement with Fluicell AB (publ), granting Ambusol worldwide rights to apply Fluicell’s microfluidic technology in cancer treatment. The partnership provides Ambusol with a unique platform for precise delivery of therapeutic compounds directly into tumors, initially […]
Minutes of the General Meeting 2025 Ambusol AB (publ) has held an Extraordinary General Meeting where shareholders resolved to authorize the Board of Directors to issue new shares to strengthen the company’s capital base ahead of upcoming clinical studies. All resolutions were passed in accordance with the Board’s proposals.
Planning Phase Between June 11 and June 19, 2025, the company visited four hospitals in China as part of its ongoing clinical outreach and partnership development efforts. Planning Phase: Multi-center clinical trials in China (40 GBM patients across 4 hospitals).
Notice of Annual General Meeting 2025 Ambusol AB (publ) hereby gives notice of the Annual General Meeting to be held on June 26, 2025, in Stockholm. The agenda includes adoption of the income statement and balance sheet, discharge from liability for the Board and CEO, and election of board members. Full notice and related documents […]